Logo
INFINI Premium V10 PLLA (Volumetric Stimulator 365 mg)

INFINI Premium V10 PLLA (Volumetric Stimulator 365 mg)

INFINI

Aesthetic dermatology
  • CE Class III certified absorbable poly L Lactic acid dermal filler (INFINI Premium Filler V10) as stated by European distributors and the brand
  • Registered by ANMAT (Argentina) in the National Registry of Producers and Medical Technology Products (RPPTM) as an absorbable sterile PLLA dermal filler, brand INFINI PREMIUM FILLER V10, for professional use in healthcare institutions
  • Registered in Lithuania as a sterile absorbable poly L Lactic acid skin filler (INFINI PREMIUM FILLER V10) manufactured by PRP Science Co., Ltd., Korea
  • Manufactured in compliance with ISO medical device quality management standards (including ISO 13485) according to information provided for the INFINI Premium Filler line
Poly-L-lactic acid (PLLA) collagen-stimulating volumetric dermal filler

Description

INFINI Premium V10 PLLA is an advanced volumetric biostimulator based on poly-L-lactic acid (PLLA), supplied as a freeze-dried sterile powder (365 mg) in a vial. It is designed to lift the skin, restore lost facial volume and correct a wide range of skin defects, including wrinkles, furrows, scars, fatty tissue atrophy and loss of elasticity. By stimulating fibroblasts to produce new collagen and replenishing atrophic fat tissue, V10 gradually improves skin tone, density, thickness and elasticity. The treatment remodels facial contours, restores harmonious facial proportions and delivers long-lasting, natural-looking rejuvenation. It is injected into the deep dermis or subcutaneous tissue by trained medical professionals and provides progressive results as new collagen forms over several months.

Bnefits

  • Powerful volumetric stimulation using poly-L-lactic acid to restore lost volume and lift the skin
  • Gradual, natural-looking rejuvenation via controlled stimulation of collagen synthesis
  • Effective correction of wrinkles, furrows, scars and fatty tissue atrophy
  • Improves skin quality by increasing density, thickness, firmness and elasticity
  • Remodels and refines facial contours, restoring more youthful facial proportions
  • Long-lasting results, with effects typically maintained for 18–24 months after a treatment series
  • Freeze-dried powder formulation allows controlled reconstitution for optimal consistency
  • Suitable for treatment of both face and selected body areas in experienced hands
  • CE Class III certified absorbable PLLA dermal filler with documented regulatory approvals
  • Designed for professional use only, providing a regenerative alternative to traditional volumising fillers

Indications

  • Treatment of severe facial wrinkles and folds such as deep nasolabial folds
  • Correction of volume defects and facial lipoatrophy
  • Improvement of facial contour deformities and loss of definition (cheeks, jawline, etc.)
  • Volumetric lifting of the face and restoration of youthful facial proportions
  • Remodelling of facial contours and improvement of skin sagging
  • Reduction of wrinkles, furrows and certain atrophic scars
  • Rejuvenation and thickening of skin with loss of elasticity and density
  • Selected body indications (such as volume loss or skin laxity in appropriate areas) as determined by a qualified practitioner

Composition

  • Poly-L-lactic acid (PLLA) 150 mg
  • Sodium carboxymethylcellulose 90 mg
  • Mannitol 125 mg
  • Total content per vial: 365 mg freeze-dried sterile powder

Formulation

  • Sterile, absorbable poly-L-lactic acid dermal filler supplied as a freeze-dried (lyophilised) powder in a vial
  • Intended to be reconstituted with sterile diluent according to the instructions for use before injection
  • Injectable suspension of PLLA microspheres for deep dermal or subcutaneous administration
  • Non-hyaluronic acid, collagen-stimulating biostimulator with gradual volumetric action

Packaging

  • Single carton containing 1 sterile vial x 365 mg of freeze-dried poly-L-lactic acid-based dermal filler
  • Labelled for professional use only and supplied with instructions for use
  • CE-marked Class III medical device packaging with batch number and expiry date for traceability

Usage

  • For exclusive use by trained healthcare professionals who meet the legal and accreditation requirements of their country.
  • Reconstitute the freeze-dried product with the recommended volume of sterile diluent (such as sterile water for injection or according to the official instructions for use) and mix thoroughly until a homogeneous suspension is obtained, using appropriate mixing techniques or devices (e.g. vortex mixer designed for V10 if available).
  • Before treatment, take a detailed medical history, assess indications and contraindications, and obtain informed consent.
  • Cleanse and disinfect all planned injection areas using strict aseptic technique.
  • Inject the reconstituted Infini V10 PLLA into the deep dermis or subcutaneous tissue, following the injection depths, techniques and recommended volumes specified in the instructions for use and local clinical guidelines.
  • Typical indications include treatment of severe facial wrinkles and folds, volume defects, lipoatrophy and contour deformities; the product should be injected only into the lower dermal layers or hypodermis, avoiding superficial placement.
  • Use appropriate techniques such as linear threading, fanning, cross-hatching or small-volume boluses, ensuring slow injection and careful aspiration where indicated to minimise the risk of intravascular injection.
  • Do not exceed the total recommended volume per session; official instructions specify typical per-area and total session volumes that should not be surpassed.
  • After injection, gently massage treated areas to distribute the product evenly and help minimise the risk of papules or nodules; many protocols recommend patient self-massage following the “5-5-5” rule (5 times per day, 5 minutes each, for 5 days) or comparable guidance to support uniform dispersion.
  • Schedule a series of treatment sessions (commonly 2–3 sessions spaced several weeks apart) based on the patient’s degree of volume loss and clinical objectives, with adjustments according to response and safety.
  • Provide post-procedure instructions, including avoidance of extreme temperatures, vigorous exercise, and facial treatments for a short period, and clear guidance on massage and signs of potential complications requiring urgent review.

Contraindications

  • Known hypersensitivity or allergy to poly-L-lactic acid, sodium carboxymethylcellulose, mannitol or any component of the product
  • Pregnancy or breastfeeding (as a precaution common to injectable aesthetic biostimulators)
  • Patients under 18 years of age
  • Active skin infections, inflammation or lesions at or near the intended treatment site (e.g. bacterial, viral or fungal infections, severe acne, dermatitis or herpes outbreaks)
  • History of severe allergic reactions or anaphylaxis without appropriate specialist evaluation and risk management
  • Autoimmune diseases or immune disorders unless carefully evaluated and approved by a specialist who is familiar with PLLA biostimulators
  • Bleeding disorders or significant use of anticoagulant/antiplatelet therapy without appropriate medical assessment and risk mitigation
  • History of keloid formation or hypertrophic scarring in areas planned for injection, unless risk–benefit has been carefully considered
  • Previous permanent fillers or incompatible implants in the intended treatment area where there may be a risk of interaction or displacement

Adverse Effects

  • Common, usually transient injection-site reactions such as redness, swelling, tenderness, pain, bruising or haematoma
  • Temporary induration, palpable papules or nodules that may arise if the product is not adequately reconstituted, distributed or massaged; many resolve with time or massage but may require clinical management
  • Transient itching, warmth or discomfort in the treated area
  • Rare inflammatory or hypersensitivity reactions, including delayed-onset nodules or granulomatous responses requiring medical evaluation and treatment
  • Very rare but serious complications such as accidental intravascular injection, which can lead to vascular occlusion, ischaemia or tissue necrosis, particularly in high-risk anatomical zones
  • Risk of infection at the injection site if aseptic technique and aftercare instructions are not strictly followed
  • As with other injectable treatments, unintended asymmetry or irregularity may occur and may require further correction or management

Storage Conditions

  • Store in the original packaging, protected from light and moisture.
  • Keep at controlled room temperature, typically below 30 °C, as specified in regulatory documentation; do not freeze.
  • Avoid exposure to excessive heat, direct sunlight or conditions outside the recommended storage range.
  • Do not use after the expiry date printed on the packaging.
  • This product is single-use only; do not resterilise or reuse a vial once opened, and discard any unused reconstituted suspension according to local regulations.
  • Keep out of reach of children and store securely in a professional healthcare environment.

Duration

Clinical improvement develops gradually over several weeks to months as new collagen is formed. A typical protocol involves 2\u20133 treatment sessions spaced approximately 4\u20136 weeks apart. The volumetric and skin-quality benefits may persist for around 18\u201324 months or longer after completion of the treatment series, depending on individual factors, lifestyle and the treatment plan.

Onset

Results are progressive rather than immediate. Some early improvement in skin texture and firmness may be noticed after a few weeks, but the main volumetric effect usually becomes increasingly visible from approximately 2\u20133 months after the first session, with collagen production and clinical benefits continuing to build for up to 6 months following treatment.

Browse more Aesthetic dermatology

Top Treatments

Top Cities in the UK